OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

T.M. Kim, Valentina Guarneri, V. Pei Jye, Linda Khaw, Jin‐Ji Yang, Marie Wislez, Chiun‐Sheng Huang, Liam Chong Kin, Julien Mazières, L.M. Tho, H. Hayashi, Nguyễn Thị Hồng Nhung, Puey Ling Chia, Filippo de Marinis, Jo Raskin, Qing Zhou, G. Finochhiaro, Xiuning Le, Daniel S.W. Tan, Sabine Brutlach, Aurora O’Brate, Svenja Adrian, K. Berghoff, Barbara Ellers‐Lenz, Niki Karachaliou, Yi‐Long Wu